Question Bank › The knock on the company is going stale

The knock on the company is going stale

The knock on the company is going stale: this quarter's own facts cut against the standing doubt

Calls Tested
287
Answered YES
68
Hit Rate
23.7%
rare by design

RLX Technology Inc. (RLX) — this company's answers

NO on the Q1 2022 call 2022-05-20 C
The model's full reasoning — Q1 2022 call → NO我们根据提供的财报电话会议记录,判断是否存在一个明确的、公司特定的疑虑,并且本季度的实际运营证据是否明显反驳了该疑虑。 首先,寻找疑虑。在电话会议中,管理层多次提到监管变化、过渡期、许可证申请等。分析师的问题也涉及监管、竞争、库存等。但我们需要一个具体的、公司特定的疑虑,比如“公司能否盈利”、“产品需求是否持续”、“监管是否导致业务下滑”等。 从记录中,管理层提到“我们仍然相信我们的战略,并致力于建立和增强我们品牌的信任度。”以及“我们相信我们的产品将通过审查并适时成功上市。”这些是信心表达,但可能不是针对一个明确的疑虑。 分析师的问题:Charlie Chen问“销售势头”,Peihang Lyu问“库存水平”和“成本削减”。这些是常规问题,没有明确指向一个长期存在的疑虑。 然而,管理层在开场白中提到了“电子烟行业正在被监管发展和高质量销售产品的需求重塑”,并说“我们完全接受这些新法规”。这暗示了监管不确定性是一个担忧,但这是行业层面的,不是公司特定的。 再仔细看,管理层提到“我们相信我们满足了相关申请要求”,以及“我们相信我们的产品将通过审查”。这可能是对监管审批的担忧,但这是过渡性的。 另一个可能的疑虑是“公司能否适应新监管环境并保持市场份额”。管理层说“我们相信我们的市场领导地位基于这些关键因素,而不是排他性”,这回应了关于竞争格局的问题。 但我们需要一个明确的、公司特定的疑虑,比如“公司是否依赖单一市场”或“公司是否面临需求下降”。在记录中,没有明确提到这样的疑虑。 分析师的问题没有直接提出一个长期存在的疑虑。管理层也没有明确承认一个特定的怀疑。 因此,可能没有符合要求的疑虑。或者,疑虑可能是“监管变化将导致业务大幅下滑”,但管理层用实际数据回应了吗?他们提到了第一季度收入下降,但归因于COVID和监管,并说第二季度表现强劲。但这是否是“本季度的实际证据”反驳了疑虑?他们提到“自3月下旬以来,我们一直在更好地履行分销商订单,本季度至今的表现强劲,符合我们的预期。”这是实际发生的,但这是否明确反驳了一个疑虑?疑虑可能是“监管将导致需求崩溃”,但管理层说“我们看到了强劲的复苏”,这可能是反驳。 然而,我们需要一个“公司特定的疑虑”,而不是行业性的。也许疑虑是“公司能否在监管下生存”,但管理层说他们已申请许可证,并相信会获得。这是计划,不是实际事件。 再考虑:管理层提到“我们已开发出符合国家标准的电子烟弹和设备,并提交给国家烟草专卖局进行技术审查。”这是行动,但结果未知。 另一个角度:分析师问“零售商可能会增加更多品牌”,管理层回应说“我们相信我们的市场领导地位基于NPS、品牌资产等,而不是排他性。”这回应了竞争疑虑,但这是观点,不是实际证据。 也许疑虑是“公司依赖单一市场(中国)”,但记录中没有提到。 我认为,记录中没有明确显示一个“长期存在的、公司特定的疑虑”被分析师或管理层明确提及。管理层在回应问题时,更多是提供信心和计划,而不是用实际数据反驳一个已知的疑虑。 因此,答案应为NO。

← Back to the full RLX analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: Reading this call as a whole, can you identify ONE well-defined DOUBT that has clearly been weighing on how this company is perceived — a standing knock evident from the transcript itself, such as skepticism that its losses will ever end, that its main product or model will find repeat demand, that its legacy business's decline will swamp everything else, that it depends too heavily on one customer, market, or financing source, or another comparable company-specific concern — AND does the CURRENT PERIOD'S OWN OPERATING EVIDENCE, as recounted by management, move clearly AGAINST that doubt? Answer YES when BOTH halves come through in the transcript, in whatever form fits the business: (1) A STANDING, COMPANY-SPECIFIC DOUBT IS VISIBLE ON THE CALL. The transcript itself shows that a particular concern has hung over this company — through analysts returning to it, management acknowledging what skeptics or investors have worried about, or management plainly addressing a question it knows the audience carries (can this business make money, will anyone buy this at scale, will the decline stop, can they fund themselves, will the big customer stay). The doubt must be specific to this company's situation, not generic macro gloom, and must read as something that predates this quarter rather than arising on this call. (2) THIS PERIOD'S REAL ACTIVITY CUTS AGAINST IT. Management recounts concrete things that actually happened in the recent period — actual orders, customers returning or expanding, real revenue or volumes where there had been little, losses narrowing because of how the business itself is now running, the doubted product performing in real use, the feared departure or decline not occurring while something better did — described with enough operating substance that the contradiction rests on observed events rather than on reassurance, plans, or projections. The evidence need not fully settle the doubt; what matters is that the current period's facts point the other way and management engages the doubt with those facts. Answer NO if no company-specific doubt is discernible — an ordinarily healthy company reporting a routine quarter. NO if the doubt exists but management answers it mainly with confidence, vision, targets, or hoped-for improvements rather than with things that already happened. NO if the period's evidence actually confirms the doubt (the losses widened, the decline continued, the customer left) and management is excusing it. NO if the contrary evidence is a one-time item, an asset sale, a financing, or something management itself treats as non-recurring rather than the business operating differently. NO if the doubt and the evidence never connect — strong facts reported on one topic while the standing concern sits elsewhere untouched. NO if the doubt appears only as boilerplate risk language or an analyst aside that management never engages. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
IFS Intercorp Financial Services Inc. Q1 2024 2024-05-14 C+
PRA ProAssurance Corporation Q1 2024 2024-05-11 D
LTRX Lantronix, Inc. Q3 2024 2024-04-29 C
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
GL Globe Life Inc. Q1 2024 2024-04-23 F
ASM Avino Silver & Gold Mines Ltd. Q4 2023 2024-03-21 C+
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
HP Helmerich & Payne, Inc. Q1 2024 2024-01-30 C
PFE Pfizer Inc. Q4 2023 2024-01-30 F
QTRX Quanterix Corporation Q3 2023 2023-11-07 B
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
DASH DoorDash, Inc. Q3 2023 2023-11-01 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
BZUN Baozun Inc. Q2 2023 2023-08-28 D
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
BXSL Blackstone Secured Lending Fund Q1 2023 2023-05-10 A
FTHM Fathom Holdings, Inc. Q1 2023 2023-05-10 C
SPIR Spire Global, Inc. Q1 2023 2023-05-10 B
SBRA Sabra Health Care REIT, Inc. Q1 2023 2023-05-04 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
TOST Toast, Inc. Q4 2022 2023-02-16 C+
PKOH Park-Ohio Holdings Corp. Q3 2022 2022-11-13 B
CLSD Clearside Biomedical, Inc. Q3 2022 2022-11-09 C
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
CHE Chemed Corporation Q3 2022 2022-11-01 B+
YMM Full Truck Alliance Co. Ltd. Q2 2022 2022-08-25 C+
EXFY Expensify, Inc. Q2 2022 2022-08-12 D
WD Walker & Dunlop, Inc. Q2 2022 2022-08-09 C+
DM Desktop Metal, Inc. Q2 2022 2022-08-08 F
XHR Xenia Hotels & Resorts, Inc. Q2 2022 2022-08-05 A
LIN Linde plc Q2 2022 2022-07-28 B+
CME CME Group Inc. Q2 2022 2022-07-27 B
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
SE Sea Limited Q1 2022 2022-05-17 F
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
FARM Farmer Bros. Co. Q3 2022 2022-05-07 D
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
STC Stewart Information Services Corporation Q1 2022 2022-04-29 C+
LOW Lowe's Companies, Inc. Q3 2021 2021-11-17 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
IPGP IPG Photonics Corporation Q3 2021 2021-11-02 C
SXC SunCoke Energy, Inc. Q3 2021 2021-11-01 A
EMR Emerson Electric Co. Q3 2021 2021-08-04 B+
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
GECC Great Elm Capital Corporation Q3 2018 2018-11-13 B
UMH UMH Properties, Inc. Q3 2018 2018-11-02 C+
FOSL Fossil Group, Inc. Q1 2018 2018-05-08 C
BCOV Brightcove Inc. Q1 2018 2018-04-26 B+
AVT Avnet, Inc. Q2 2018 2018-01-25 B
PII Polaris Inc. Q3 2017 2017-10-24 C+
GNTX Gentex Corporation Q3 2017 2017-10-20 B
MTG MGIC Investment Corporation Q3 2017 2017-10-18 B+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
BIIB Biogen Inc. Q2 2017 2017-07-25 B
CAG Conagra Brands, Inc. Q2 2017 2016-12-22 C+
WYY WidePoint Corporation Q3 2016 2016-11-09 D
ULBI Ultralife Corporation Q3 2016 2016-10-29 C+
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
GES Guess?, Inc. Q1 2017 2016-05-25 F
RCL Royal Caribbean Cruises Ltd. Q1 2016 2016-04-29 C+
DD DuPont de Nemours, Inc. Q1 2016 2016-04-26 B+
HPP Hudson Pacific Properties, Inc. Q4 2015 2016-02-25 C

How the model reasoned

BRX · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible on the call, and if this period's operating evidence cuts against it. YES The standing doubt is the skepticism that tenant disruptions (especially bankruptcies like Bed Bath) will create occupancy pressure and throw markets out of equilibrium, given the recaptured space and potential for more filings. This is visible in analyst questions (Todd Thomas on Bed Bath impact and market equilibrium; others circling back on bad debt 75-110 bps and bankruptcy activity) and management's acknowledgment that "recent retailer bankruptcy announcements will result in occupancy pressure" while noting they've "been preparing for the last several quarters." This period's evidence cuts against it: record 94% total occupancy (up sequentially in a seasonally weak quarter), small-shop at 89.
CME · Q2 2022 → YESThe question is: Identify ONE well-defined DOUBT that has been weighing on the company, and see if the current period's operating evidence moves against that doubt. YES The standing doubt is the perceived risk that the legacy NEX Group businesses (BrokerTec and EBS) would continue to show range-bound revenue and fail to deliver meaningful growth despite a constructive macro backdrop, as directly raised by Alex Blostein. Management engages this concern head-on by recounting concrete operating evidence from 2Q: BrokerTec US treasuries ADV up 14% YoY, US repo up 25% YoY, EU repo up 14% YoY, plus $4.5 billion in new cross-sell volume from previously non-trading clients and record RV trading volumes of $2.4 billion; 90% of the migration to Globex is complete, with the remaining EBS migration also finished and system enhancements underway.
BXSL · Q1 2023 → YESThe question asks if there's a standing company-specific doubt visible in the transcript, and if this period's operating evidence moves against it. YES The standing doubt visible in the transcript is the skepticism that BXSL’s credit performance will be materially worse than the broader private-credit market because of its exposure to higher-rate environments and the “tails” of the portfolio (i.e., the small slice of companies whose interest-coverage ratios could fall below 1× when 5 % rates are stress-tested). Management itself flags this concern by noting that “it is less about averages… much more about the tails” and that investors keep asking about the percentage of the portfolio below 1× ICR. This quarter’s operating evidence directly counters that doubt: - 0.

More from the question bank

Acted like it's already biggerBetting on a claim they haven't proven yetMoney already collected for work not yet donNew faces on the callThe streak is aliveCommitted past the numbersAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.